|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
March 02, 2006
TYSABRI 'S COMPETITORS HOPE THAT FDA DOESN'T APPROVE ITS RETURN!...READ MORE
"The FDA ruling will be closely watched by the industry because it will determine the fate of Serono, Europe's biggest biotech group.Serono makes Rebif, a leading multiple sclerosis drug, and if Tysabri does not return to the market or is restricted, then the Swiss firm could be bid for by either GlaxoSmithKline, or AstraZeneca, Serono was put up for sale by its biggest shareholder, the Bertarelli family, in November." |